|Previous Section||Index||Home Page|
Michael Fabricant: To ask the Secretary of State for Health how many civil servants and what percentage of the total civil service work force in his Department will be relocated over the next five years (a) outside the M25, (b) to the West Midlands and (c) to Staffordshire. 
Ms Rosie Winterton: The Lyons report gives details of the Department's relocations plans, which are being taken forward and refined as part of the spending review. The Government will announce proposals for implementing and monitoring the dispersal plans in the review. The Department will then decide on its dispersal strategy in light of its business needs and priorities.
Tony Lloyd: To ask the Secretary of State for Health what representations he has received about the impact of the recommendations of the Royal College of Physicians on domiciliary oxygen services on cluster headache sufferers; and if he will make a statement. 
Ms Rosie Winterton
[holding answer 22 June 2004]: Representations have been received from the organisations Headache UK and Ouch (Organisation for the Understanding of Cluster Headaches) about the changes to the domiciliary oxygen service which will be introduced next year. Patients suffering from cluster headaches will continue to be able to receive the oxygen service which they need.
28 Jun 2004 : Column 105W
Chris Ruane: To ask the Secretary of State for Health how many dentists per 10,000 head of population there have been in each of the past 25 years; and what the projection is for the next five years. 
Ms Rosie Winterton [holding answer 4 June 2004]: There are no plans to introduce free dental care for pensioners. It is the Department's policy to offer help with health costs based upon a person's income.
Mr. Drew: To ask the Secretary of State for Health if he will set out, with statistical evidence relating as closely as possible to the Stroud constituency, the effects of changes to departmental policy since 1997 on the Stroud constituency. 
Ms Rosie Winterton:
The Government has put in place a programme of National Health Service investment and reform since 1997 to improve service
28 Jun 2004 : Column 106W
delivery in all parts of the United Kingdom. There is significant evidence that these policies have yielded considerable benefits for the Stroud constituency.
At the end of March 2004, the number of people waiting more than nine months for inpatient treatment within Cotswold and Vale Primary Care Trust (PCT) has fallen to zero, from 113 in June 2002.
At the end of March 2004, the number of patients waiting over 13 weeks for outpatient treatment within Cotswold and Vale PCT has fallen to 83, from 396 in June 2002.
In 2002, at Gloucestershire Hospitals NHS Trust, 87.1 per cent., of patients spent less than four hours in accident and emergency from arrival to admission, transfer or discharge. Figures for December 2003 show an improvement to 94.2 per cent.
Between September 2002 and September 2003, the number of consultants at Gloucestershire Hospitals NHS Trust has increased from 205 to 226. The number of nurses increased from 1,928 to 2,152.
In September 2002, figures show 157 general practitioners within Cotswold and Vale PCT. Figures for December 2003 show an increase to 163.
Figures for December 2003 show that all patients within Cotswold and Vale PCT are able to be offered an appointment with a primary care professional within two working days.
In the Stroud local authority area, death rates from cancer per 100,000 population have fallen to 163.5 in 2002, from 168.1 in 1997.
In the Stroud local authority area, death rates from coronary heart disease per 100,000 population have fallen to 129 in 2002, from 132 in 1997.
Cotswold & Vale PCT's allocation has risen to £173.6 million for 200405; a cash increase of 8.9 per cent..
£30 million investment in a private finance initiative redevelopment at Gloucestershire Royal Hospital to provide modern, state of the art health care facilities, anticipated to open in Autumn 2004.
£8.5 million invested in four new operating theatres and oral and maxillofacial laboratory and a medical engineering department at Gloucestershire Royal Hospital.
(2) what research his Department has evaluated on the suitability of synthetic insulin for all diabetics in the United Kingdom; and if he will make a statement; 
(3) how many patients he estimates are more suited to animal insulin and have experienced problems with synthetic insulin; and if he will make a statement. 
Ms Rosie Winterton:
All authorised insulins, whether human (synthetic) insulin or animal insulin, have been demonstrated to be efficacious in people with diabetes mellitus. As part of the licensing approval process for any medicinal product, including insulins, the applicant has to provide evidence that the product meets appropriate standards of quality, safety and efficacy. This will include clinical trial data in patients with diabetes. The decision to use one or other of the insulins rests with the physician in consultation with the patient.
28 Jun 2004 : Column 107W
The Committee on Safety of Medicines and its sub-committee on pharmacovigilance (SCOP) has kept the safety of synthetic (human) insulins under close review and has considered the available data on a number of occasions. Most recently in 2002, the SCOP considered the findings of an independent review of controlled clinical trial data by the Cochrane collaboration. The conclusions of the Cochrane review were that there is no difference in the incidence of adverse events between patients on synthetic insulin compared with patients on animal insulins. The SCOP confirmed its previous advice that there is no clear evidence of safety problem specific to human insulin. However, the issue will be reviewed again should further information become available.
|Highly purified animal insulin||181.0|
|Human sequence (GM Insulin)||3,654.3|
|Next Section||Index||Home Page|